- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00457925
Absorption, Distribution, Metabolism And Excretion Study For GSK221149A
March 15, 2012 updated by: GlaxoSmithKline
An Open-label, Two Period Study to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK221149A, Administered as Single Doses of an Oral Solution and an Intravenous Infusion to Healthy Female Volunteers
This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion criteria:
- Healthy adult, non-smoking females
- Aged between 30 - 55 years old, and BMI of between 19 and 32
- Not of child-bearing potential
Exclusion criteria:
- No clinically significant findings on clinical examination, medical examination and blood tests.
- Radiation exposure over previous 3 years is greater than 10mSv
- History of bleeding or gastric problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Urinary and fecal cumulative excretion as a percentage of the total radioactive dose administered over time. Collection of plasma, urine and fecal samples for assessment of metabolites. Samples are collected for approximately 7 days (or longer).
|
Secondary Outcome Measures
Outcome Measure |
---|
Clinical Safety data. PK parameters of GSK221149A and drug-related material (radioactivity) in plasma following oral and intravenous dosing. Samples are collected for approximately seven days (or longer) following dosing.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Study Registration Dates
First Submitted
April 6, 2007
First Submitted That Met QC Criteria
April 6, 2007
First Posted (ESTIMATE)
April 9, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
March 19, 2012
Last Update Submitted That Met QC Criteria
March 15, 2012
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OTA105101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstetric Labour, Premature
-
GlaxoSmithKlineCompletedObstetric Labour, PrematureUnited States
-
GlaxoSmithKlinePPDTerminatedObstetric Labour, PrematureBelgium, Germany, Israel, Italy, Korea, Republic of, Mexico, Spain, Sweden, United Kingdom
-
GlaxoSmithKlineCompletedObstetric Labour, PrematureUnited States
-
GlaxoSmithKlineCompletedObstetric Labour, PrematureUnited States
-
GlaxoSmithKlineCompletedObstetric Labour, PrematureUnited States
-
GlaxoSmithKlinePPDTerminatedObstetric Labour, PrematureUnited States, Italy, United Kingdom, Japan, Canada
-
GlaxoSmithKlinePPDCompletedObstetric Labour, PrematureGermany, Israel, Italy, Korea, Republic of, Mexico, Spain, Belgium, United Kingdom, Sweden, United States, Japan
-
Assistance Publique Hopitaux De MarseilleUnknownPremature LabourFrance
-
Mohamed Sayed AbdelhafezRecruiting
-
GlaxoSmithKlineCompletedObstetric Labour, PrematureUnited States, France, Bulgaria, Spain, Korea, Republic of, Singapore, Colombia, United Kingdom, Lithuania, Puerto Rico, Argentina
Clinical Trials on GSK221149A
-
GlaxoSmithKlineCompletedObstetric Labour, PrematureUnited States, France, Bulgaria, Spain, Korea, Republic of, Singapore, Colombia, United Kingdom, Lithuania, Puerto Rico, Argentina